SG/CALL/VERTEX PHARMACEUTICALS/550/0.1/19.09.25 | Real-time Bid/Ask 09:48:12 22/05/2024 pm IST | ||
| 3.66 EUR / 3.72 EUR | +1.93% |
|
| Current month | +74.88% | ||
| 1 month | +56.03% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 22/24/22 | 3.45 | -4.70% |
| 21/24/21 | 3.62 | +4.32% |
| 20/24/20 | 3.47 | +2.66% |
| 17/24/17 | 3.38 | +2.11% |
| 16/24/16 | 3.31 | +10.70% |
Delayed Quote Börse Stuttgart
Last update May 22, 2024 at 01:22 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SU95V8 |
| ISIN | DE000SU95V88 |
| Date issued | 01/03/2024 |
| Strike | 550 $ |
| Maturity | 19/09/2025 (485 Days) |
| Parity | 10 : 1 |
| Emission price | 3.9 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.86 € |
|---|---|
| Lowest since issue | 2.07 € |
| Spread | 0.06 € |
| Spread % | 1.62% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
442
USD
Average target price
462.8
USD
Spread / Average Target
+4.71%
- Stock Market
- Warrants
- Warrant
